About Us

NephroGenex is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. Our clinical and regulatory teams positioned the Phase 3 Pyridorin program for success by securing from FDA a Fast Track designation and Special Protocol Assessment for a new endpoint and patient population. We believe Pyridorin has potential to be a breakthrough therapy in a disease for which there are few treatment options.

Learn More